Summary The efficacy of high-dose chemotherapy (HDC) and circulating progenitor cell (CPC) transplantation in metastatic breast cancer (MBC) relies mainly on giving this treatment after a response to conventional induction chemotherapy has been achieved. For this reason an optimal mobilization regimen should be therapeutically effective while minimizing the number of leucaphereses required to support the myeloablative therapy. The combination of an anthracycline and paclitaxel in chemotherapy-untreated MBC has produced impressive response rates. We evaluated the CPC-mobilizing capacity of the combination epirubicin (90 mg m-2) and paclitaxel (135 mg m-2) followed by filgrastim (5 Ag kg-1 day-1) starting 48 h after chemotherapy administration in ten patients with MBC who were eligible for an HDC and CPC transplantation programme. Leucaphereses were performed by processing at least two blood volumes per procedure at recovery from neutrophil nadir when CD34+ cells in the peripheral blood exceeded 20 [I-. In most patients (six out of 10) more than 2.5 x 106 CD34+ cells kg-', a threshold considered to be sufficient for haematopoietic reconstitution, were collected with a single apheresis. In the remaining four patients an additional procedure, performed the following day, was enough to reach the required number of progenitors. These data suggest that the epirubicin-paclitaxel combination, besides being a very active regimen in MBC, is effective in releasing large amounts of progenitor cells into circulation.
The autologous transfusion of circulating progenitor cells (CPCs) collected from the peripheral blood by leucapheresis is rapidly replacing autologous bone marrow transplantation to support haematopoiesis after high-dose chemotherapy (HDC) for lymphoma and solid tumours (Gianni AM, 1994; Holoyake, 1994) . The main reason for the success of this procedure is the capability of CPCs to produce a much faster haematopoietic recovery than bone marrow cells (Siena et al, 1989; Sheridan et al, 1992; Chao et al, 1993; Schmitz et al, 1996) .
An adequate number of progenitor cells capable of guaranteeing short-and long-term haematopoiesis can be harvested from the peripheral blood after treatment with haematopoietic growth factors administered as single agents or, more frequently, following myelosuppressive chemotherapy (Bensinger et al, 1993; Siena et al, 1994) . Moreover, mobilization with disease-oriented chemotherapy in addition to cytokines is particularly recommended in patients with chemosensitive neoplasms as the greater efficacy of mobilization is combined with the anti-tumour effect of the drug. In fact, in most CPC transplantation programmes the mobilizing regimens include agents (often at high doses) with proven efficacy against the underlying disease (Brugger et al, 1992; Shimazaki et al, 1992; Gianni AM et al, 1995) .
Controversy still surrounds the use of HDC with CPC support in stage IV breast cancer (Shpall et al, 1994; Hortobagyi, 1995; Kennedy, 1995) , mainly because of a lack of large randomized trials. However, a number of phase II studies (Peters et al, 1988; Antman et al, 1992) and two recent phase III studies (Bezwoda et al, 1995; Peters et al, 1996) have shown that this approach may result in an increase in disease-free survival and overall survival and may be curative in a small subset of patients. In addition, there is strong evidence that the efficacy of HDC in MBC is mainly dependent on the possibility of treating women who have shown a response to conventional chemotherapy regimens (Antman et al, 1992; Shpall et al, 1994) . In this scenario, an ideal first-line regimen for patients with stage IV breast cancer should have, first, the ability to induce high response rates and, second, the capacity to mobilize sufficient numbers of haematopoietic progenitors. It is already known that the combination of an antracycline and paclitaxel meets the first requirement. In fact, despite the involvement of taxanes and anthracyclines in the multiple drug resistance phenotype (Podda et al, 1992) , paclitaxel induced objective responses in 20-40% of patients who failed to respond to prior treatment with anthracyclines (Gianni L et al, 1995a; Seidman et al, 1995) , and the combination of the two resulted in impressive response rates in previously untreated women (Hortobagyi et al, 1994; Gianni L et al, 1995b; Sledge et al, 1995) .
In the present study, ten patients with MBC were given the anthracycline epirubicin and paclitaxel to achieve cytoreduction before transplantation and to facilitate CPC collection.
Data on progenitor cell harvesting and preliminary response rate are reported. 
Treatment
Patients received epirubicin 90 mg m-2 by i.v. bolus injection followed by paclitaxel 135 mg m-2 by 3-h i.v. infusion. Premedication to prevent paclitaxel-induced hypersensitivity reactions included steroids, chlorpheniramine and ranitidine. Doses and administration schedules of chemotherapeutic agents were based on previously reported studies (Buzdar et al, 1995; Gianni L et al, 1995b ) and on our own preliminary experience. Epirubicin was used instead of doxorubicin because it has the same antitumour effect and lower cardiotoxicity (Bonadonna et al, 1993) . Filgrastim was given s.c. at a dose of 5 ,tg kg-' daily starting 48 h after chemotherapy administration. Patients continued to receive filgrastim through the final day of leucapheresis. Ciprofloxacin 500 mg orally twice per day was given when the WBC count dropped below 1.5 x 109 1-'. Toxicity and response were assessed according to World Health Organization guidelines (WHO, 1979) .
All patients were programmed to receive at least three cycles of chemotherapy before response was evaluated. Complete responders were given HDC with stem cell support, whereas patients with partial response (PR) or stable disease received three more cycles of the epirubicin-paclitaxel combination. If progression was documented, a second-line treatment was given.
CPC collection
CPCs were collected after the first chemotherapy cycle in eight patients and after the second in two. Leucaphereses were performed with a continuous blood cell separator Cobe Spectra, and a minimum of two blood volumes per procedure were processed as described previously (Torretta et al, 1996) . Blood flow rate was 40-50 ml min-' and the ACD-whole blood ratio was 1:11. We routinely administered 10% calcium gluconate in continuous infusion (3.3 mmol [-1) to prevent hypocalcaemia symptoms. Collection was planned so as to obtain a product with a final haematocrit of 4%.
Leucaphereses were performed upon recovery from neutrophil nadir when circulating CD34+ cells exceeded 20 p3-'. The trigger value of 20 CD34+ cells itl-l was chosen on the basis of previous reports (Siena et al, 1991; Zimmerman et al, 1995) . Our final target for collection was a minimum of 2.5 x 106 CD34+ cells kg-' body weight. If the CD34+ cells harvested with the first collection were fewer than that amount, an additional procedure was performed the following day. When the study was designed very few data were available concerning the mobilization capacity of the epirubicin-paclitaxel combination and the threshold of CD34+ cell harvest was chosen based on previous reports (Bender et al, 1992; Bensinger et al, 1995) and our own experience. Flow cytometry Expression of the surface membrane CD34 antigen was evaluated as described previously (Siena et al, 1991 (Pettengell et al, 1994) . Values of P lower than 0.05 were considered statistically significant.
RESULTS

Chemotherapy toxicity
The median nadir of WBC and platelet counts occurred on days 7 (range 6-9) and 8 (range 6-10) respectively. Median 
CPC harvesting
Fourteen leucaphereses were performed in our ten patients. In four out of ten cases the number of CD34+ cells collected the first day was below our target (median 1.9 x 106 kg-1 body weight, range 1.2-2.2) and an additional procedure had to be performed. Median WBC and circulating CD34+ counts on the first day of collection were 11.5 x 103 lI-p (range 5.4-24.8) and 48 pl-1 (range 21-13 1) respectively (Table 2) . As a consequence of the variability in peripheral blood WBC counts, the total number of WBCs collected varied from procedure to procedure (median 28.5 x 109 range 8-63). The median time of CPC collection was the 11th day after paclitaxel-epirubicin administration (range 8-13). Most of the procedures were carried out on day 10 to day 12 (Figure 1 ).
In all cases the target of 2.5 x 106 kg-1 CD34+ cells kg-1 was reached. The median numbers of CD34+ cells collected per leucapheresis and per patient were 2.8 (range 1.2-7.8) and 4.35 (2.8-10) respectively (Figure 2) .
Finally, the median number of CAFCs per leucapheresis was 3.0 x 106 (range 0.7-4.9).
Treatment response and CPC transplantation Three patients achieved complete response (CR), four reached PR and three showed no response or progressive disease after three cycles of the epirubicin-paclitaxel combination. One PR patient obtained CR after three additional cycles of chemotherapy.
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So far, four of these patients have undergone HDC and stem cell support. All of them received the same preparative regimen, which included thiotepa, carboplatin and cyclophosphamide (Antman et al, 1992) . The median days needed to reach an absolute neutrophil count of > 0.5 x 109 1-' and a platelet count of 20 x 109 1-' were 9 and 10, respectively, after infusion of peripheral blood progenitor cells. No graft failure was observed at a median follow-up of 8.5 months (range 5-14).
DISCUSSION
Autologous CPCs are increasingly being used as a source of haematopoietic stem cells following HDC for solid tumours because of their ease of collection and the faster neutrophil and platelet recovery as compared with marrow (Siena et al, 1994) . Besides, CPCs are less likely to be contaminated by tumour cells capable of clonogenic growth in vitro (Ross et al, 1993) .
A variable number of leucaphereses are needed to harvest the optimal dose of CPCs. Collection after chemotherapy, either at conventional or high doses, followed by haematopoietic growth factor(s) administration takes advantage of the additional mobilizing effect of the myelotoxic drugs. As a consequence, the yield of the collection is more predictable and fewer leucapheresis procedures are needed.
Limited preliminary data are available regarding the use of paclitaxel alone or in combination with other agents in facilitating CPC collection. Recently, Demirer et al (1995) have shown that paclitaxel and cyclophosphamide followed by filgrastim mobilize CPC in patients with advanced ovarian and breast cancer more effectively than cyclophosphamide alone. Other authors have also reported successful stem cell harvesting after paclitaxel administration (Fennelly et al, 1995) .
Mobilizing cytotoxic agent(s) must be chosen from among those with proven activity against the underlying disease. This is especially important in those conditions, e.g. advanced breast cancer, in which transplantation is performed mainly in patients who have shown optimal response to first-line induction chemotherapy.
Despite the controversy over the number of autologous CPCs required to support myeloablative regimens, an amount greater than 2.5 x 106 kg-' body weight CD34+ cells is considered by many authors to be sufficient for a safe haematopoietic reconstitution (Bender et al, 1992; Bensinger et al, 1995; Schwella et al, 1996) . The tempo of platelet engraftment has been reported to be delayed in some patients when less than 5 x 106 CD34+ cells kg-' body weight are reinfused (Bensinger et al, 1995) . However, small differences between studies and groups of patients may reflect the difficulties in standardizing the quantitative assay used as well as being due to biological reasons related to previous exposure to chemotherapy (Tricot et al, 1995) .
In the present study, after the administration of epirubicin, paclitaxel and filgrastim, most patients reached the target of 2.5 x 106 kg-' CD34+ cells with a single leucapheresis. Interestingly, when a second harvest had to be performed, the total number of CD34+ cells was higher than that collected at the first procedure (P < 0.001).
Overall, our data suggest that a trigger value of 45 CD34+ cells tl-' in circulation indicates the best day for the apheresis procedure. In fact, five out of five patients who presented more than 45 CD34+ cells l-' collected > 2.5 x 106 CD34+ cells kg-', whereas four out of five patients with fewer than 45 CD34+ cells il-' failed to harvest an adequate amount of progenitors at the first leucapheresis procedure. In an attempt to make a single leucapheresis feasible in all patients, further optimization of harvesting timing is now under investigation on a larger number of subjects.
As a contribution towards identifying the total number of CAFCs needed for safe and rapid haematopoietic reconstitution, we used LDA to calculate the CAFC (or long-term cultureinitiating cell, LTC-IC) in leucapheresis. This is currently thought to be the best surrogate for early progenitor cell enumeration (Hows et al, 1992; Pettengell et al, 1994; Ploemacher, 1994) , and in a recent clinical study (Breems et al, 1996) a reduction of engraftment potential in CAFC-poor leucapheresis has been demonstrated. In relation to this, we are currently evaluating the correlation between the total number of CAFCs collected after various mobilization regimens and their short-and long-term engraftment potential.
In conclusion, the epirubicin-paclitaxel combination followed by filgrastim is effective in releasing large numbers of progenitor cells into the peripheral blood of patients with advanced breast cancer. Given its high therapeutic efficacy and limited toxicity we believe that this combination should be employed as induction therapy before high-dose regimens in selected patients with stage IV disease.
